亲爱的研友该休息了!由于当前在线用户较少,发布求助请尽量完整地填写文献信息,科研通机器人24小时在线,伴您度过漫漫科研夜!身体可是革命的本钱,早点休息,好梦!

Association of hepatitis B virus DNA levels with efficacy and safety outcomes in patients with hepatitis B virus-associated advanced hepatocellular carcinoma receiving tyrosine kinase inhibitor plus anti-PD-1 antibody: a multicenter propensity-matched study

医学 肝细胞癌 队列 内科学 乙型肝炎病毒 胃肠病学 HBeAg 免疫学 肿瘤科 病毒 乙型肝炎表面抗原
作者
Qing-Jing Chen,Kongying Lin,Zhi-Wen Lin,Bing Zhang,Mingqiang Liu,Jianxi Zhang,Qi-Zhen Huang,Kecan Lin,Jinyu Zhang,Fuqun Wei,Peng-Hui You,You Song,Jiang Ya-bin,Hui Zhang,Zhiqing Cheng,Cong-Ren Wang,Yongyi Zeng
出处
期刊:International Immunopharmacology [Elsevier BV]
卷期号:125: 111098-111098 被引量:3
标识
DOI:10.1016/j.intimp.2023.111098
摘要

The efficacy and safety of tyrosine kinase inhibitors (TKIs) combined with anti-PD-1 antibodies (α-PD-1) in advanced hepatocellular carcinoma (HCC) with high hepatitis B virus (HBV) DNA levels (>500 IU/mL) remain unclear. We retrospectively assessed patients from seven medical institutions diagnosed with HBV-related HCC, undergoing treatment with TKIs and α-PD-1 in conjunction with antiviral therapies. Based on HBV-DNA levels, patients were categorized into either high (HHBV-DNA, >500 IU/mL) or low HBV-DNA (LHBV-DNA, ≤500 IU/mL) cohorts Propensity score matching (PSM) was used to minimize baseline imbalance between groups. 149 patients were included, with 66 patients exhibiting HBV-DNA > 500 IU/mL and 83 patients presenting HBV-DNA ≤ 500 IU/mL. Compared with the LHBV-DNA cohort, the HHBV-DNA cohort had a greater incidence of serum HBeAg positivity, tumor diameter ≥ 10 cm, and vascular invasion. Following PSM, 57 individuals were enrolled in each group. Oncological outcomes were comparable between HHBV-DNA and LHBV-DNA cohorts before and after PSM. Before PSM, the median PFS and OS were 6.1 months and 17.5 months in the HHBV-DNA cohort and 6.7 months and 19.3 months in the LHBV-DNA cohort (all P > 0.05). After PSM, the median PFS and OS were 6.0 months and 19.5 months in the HHBV-DNA cohort and 6.0 months and 17.1 months in the LHBV-DNA cohort, respectively (all P > 0.05). Safety profiles were equivalent across cohorts with no fatal incidents reported. Seven patients (4.7 %) had HBV reactivation. 1 (0.7 %) from HHBV-DNA and 6 (4.0 %) from LHBV-DNA (P = 0.134). Only one patient developed HBV-related hepatitis. The effectiveness and safety of TKIs plus α-PD-1 in advanced HCC with HBV-DNA > 500 IU/mL were not compromised in the context of concomitant antiviral therapy.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
7秒前
nolan完成签到 ,获得积分10
22秒前
小蘑菇应助科研通管家采纳,获得10
25秒前
kk完成签到 ,获得积分10
28秒前
29秒前
Elvira完成签到,获得积分10
30秒前
先玩了玉发布了新的文献求助10
33秒前
笨笨完成签到,获得积分10
48秒前
vchen0621完成签到,获得积分0
53秒前
certe完成签到,获得积分10
55秒前
57秒前
vchen0621发布了新的文献求助10
1分钟前
先玩了玉完成签到,获得积分10
1分钟前
俞无声完成签到 ,获得积分10
1分钟前
花凉发布了新的文献求助20
1分钟前
科研通AI2S应助科研通管家采纳,获得10
2分钟前
科研通AI2S应助科研通管家采纳,获得10
2分钟前
研友_VZG7GZ应助科研通管家采纳,获得10
2分钟前
2分钟前
尊敬夜南完成签到,获得积分10
2分钟前
Cathy完成签到 ,获得积分10
2分钟前
今天看文献了吗完成签到,获得积分10
2分钟前
张晓祁完成签到,获得积分10
3分钟前
yueying完成签到,获得积分10
3分钟前
3分钟前
Owen应助尊敬夜南采纳,获得10
3分钟前
花凉完成签到,获得积分10
3分钟前
花凉发布了新的文献求助20
3分钟前
Ava完成签到,获得积分10
4分钟前
liudy完成签到,获得积分10
4分钟前
Ava发布了新的文献求助50
4分钟前
吃了吃了完成签到,获得积分10
4分钟前
liudy发布了新的文献求助10
4分钟前
领导范儿应助科研通管家采纳,获得10
4分钟前
4分钟前
阿紫吖完成签到 ,获得积分10
4分钟前
过时的白曼完成签到,获得积分10
4分钟前
隐形曼青应助三叔采纳,获得10
5分钟前
5分钟前
陈苗发布了新的文献求助10
5分钟前
高分求助中
The Mother of All Tableaux: Order, Equivalence, and Geometry in the Large-scale Structure of Optimality Theory 3000
A new approach to the extrapolation of accelerated life test data 1000
ACSM’s Guidelines for Exercise Testing and Prescription, 12th edition 500
Indomethacinのヒトにおける経皮吸収 400
Phylogenetic study of the order Polydesmida (Myriapoda: Diplopoda) 370
基于可调谐半导体激光吸收光谱技术泄漏气体检测系统的研究 350
Robot-supported joining of reinforcement textiles with one-sided sewing heads 320
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 3990031
求助须知:如何正确求助?哪些是违规求助? 3532108
关于积分的说明 11256334
捐赠科研通 3270943
什么是DOI,文献DOI怎么找? 1805146
邀请新用户注册赠送积分活动 882270
科研通“疑难数据库(出版商)”最低求助积分说明 809228